BioCardia

BCDANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$15.896 M

$1.05 -2.78%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$8.23M

Loss-making

Shares outstanding

15,138,782

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#143Dyadic InternationalDYAI$16.0M
#144Passage BIOPASG$15.9M
#145BioCardiaBCDA$15.9M
#146PluriPLUR$13.6M
#147Intensity TherapeuticsINTS$13.1M

Insiders buying

All insider buying →

3 open-market purchases by officers and directors of BioCardia, worth $10.7K. Grants and option exercises are excluded.

Peter AltmanPresident and CEO$5.02K
5,400 shares at $0.93 on 17 Aug 2026 · filed 18 Aug 2026
Peter AltmanPresident and CEO$1.75K
1,900 shares at $0.92 on 13 Aug 2026 · filed 13 Aug 2026
Peter AltmanPresident and CEO$3.90K
5,000 shares at $0.78 on 29 Jul 2026 · filed 29 Jul 2026

What if BioCardia were worth as much as…

Open the what-if tool →

Gold $30.2T

$1,997,120

Per share 1,902,019× higher

Bitcoin $1.74T

$115,045.92

Per share 109,568× higher

Nvidia $5.52T

$364,346.82

Per share 346,997× higher

Or at a round number

$20.0M $50.0M $100.0M $200.0M

Where these numbers come from

Share counts and financials for BioCardia are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.